RT Journal Article
SR Electronic
T1 Safety, Immunogenicity, and Efficacy of a COVID-19 Vaccine (NVX-CoV2373) Co-administered With Seasonal Influenza Vaccines
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.09.21258556
DO 10.1101/2021.06.09.21258556
A1 Toback, Seth
A1 Galiza, Eva
A1 Cosgrove, Catherine
A1 Galloway, James
A1 Goodman, Anna L.
A1 Swift, Pauline A.
A1 Rajaram, Sankarasubramanian
A1 Graves-Jones, Alison
A1 Edelman, Jonathan
A1 Burns, Fiona
A1 Minassian, Angela M.
A1 Cho, Iksung
A1 Kumar, Lakshmi
A1 Plested, Joyce S.
A1 Rivers, E. Joy
A1 Robertson, Andreana
A1 Dubovsky, Filip
A1 Glenn, Greg
A1 Heath, Paul T.
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/06/13/2021.06.09.21258556.abstract
AB Background The safety and immunogenicity profile of COVID-19 vaccines when administered concomitantly with seasonal influenza vaccines has not yet been reported.Methods A sub-study on influenza vaccine co-administration was conducted as part of the phase 3 randomized trial of the safety and efficacy of NVX-CoV2373. The first ∼400 participants meeting main study entry criteria and with no contraindications to influenza vaccination were invited to join the sub-study. After randomization in a 1:1 ratio to receive NVX-CoV2373 (n=217) or placebo (n=214), sub-study participants received an age-appropriate, licensed, open-label influenza vaccine with dose 1 of NVX-CoV2373. Reactogenicity was evaluated via electronic diary for 7 days post-vaccination in addition to monitoring for unsolicited adverse events (AEs), medically-attended AEs (MAAEs), and serious AEs (SAEs). Influenza haemagglutination inhibition and SARS-CoV-2 anti-spike IgG assays were performed. Vaccine efficacy against PCR-confirmed, symptomatic COVID-19 was assessed. Comparisons were made between sub-study and main study participants.Findings Sub-study participants were younger, more racially diverse, and had fewer comorbid conditions than main study participants. Reactogenicity events more common in the co-administration group included tenderness (70.1% vs 57.6%) or pain (39.7% vs 29.3%) at injection site, fatigue (27.7% vs 19.4%), and muscle pain (28.3% vs 21.4%). Rates of unsolicited AEs, MAAEs, and SAEs were low and balanced between the two groups. Co-administration resulted in no change to influenza vaccine immune response, while a reduction in antibody responses to the NVX-CoV2373 vaccine was noted. Vaccine efficacy in the sub-study was 87.5% (95% CI: -0.2, 98.4) while efficacy in the main study was 89.8% (95% CI: 79.7, 95.5).Interpretation This is the first study to demonstrate the safety, immunogenicity, and efficacy profile of a COVID-19 vaccine when co-administered with seasonal influenza vaccines. The results suggest concomitant vaccination may be a viable immunisation strategy.Funding This study was funded by Novavax, Inc.Evidence before this study We searched PubMed for research articles published from December 2019 until 1 April 2021 with no language restrictions for the terms “SARS-CoV-2”, “COVID-19”, “vaccine”, “co-administration”, and “immunogenicity”. There were no peer-reviewed publications describing the simultaneous use of any SARS-CoV-2 vaccine and another vaccine. Several vaccine manufacturers had recent publications on phase 3 trials results (Pfizer/BioNTech, Moderna, AstraZeneca, Janssen, and the Gamaleya Research Institute of Epidemiology and Microbiology). Neither these publications nor their clinical trials’ protocols (when publicly available) described co-administration and they often had trial criteria specifically excluding those with recent or planned vaccination with any licenced vaccine near or at the time of any study injection.Added value of this study Immune interference and safety are always a concern when two vaccines are administered at the same time. This is the first study to demonstrate the safety and immunogenicity profile and clinical vaccine efficacy of a COVID-19 vaccine when co-administered with a seasonal influenza vaccine.Implications of all the available evidence This study provides much needed information to help guide national immunisation policy decision making on the critical issue of concomitant use of COVID-19 vaccines with influenza vaccines.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04583995; https://clinicaltrials.gov/ct2/show/NCT04583995Clinical Protocols https://www.medrxiv.org/content/10.1101/2021.05.13.21256639v1.supplementary-material https://www.novavax.com/sites/default/files/2021-04/2019nCoV_302_Phase3UK%20_Version4_Redacted.pdf https://clinicaltrials.gov/ct2/show/NCT04583995 Funding StatementThis study was funded by Novavax, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial protocol was approved by the North West Greater Manchester Central Research Ethics Committee (Ref 20/NW/03/99) and was performed in accordance with the International Council for Harmonisation Good Clinical Practice guidelines. Safety oversight was performed by an independent safety monitoring committee. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe protocol for this phase 3 study is publicly available from Novavax. https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004123-16/GB